Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colorectal Adenocarcinoma: early-phase trial registry
10 of 20 indexed Colorectal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 10 currently recruiting · #848 of 28,707 conditions by registered trial count
Colorectal Adenocarcinoma: 20 US clinical trials tracked, 10 recruiting.
Colorectal Adenocarcinoma is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 4 of these trials.
Enrollment posture brief
Registry condition colorectal-adenocarcinoma
OPEN 10 | RECR 50% | LATE 1 | EARLY 12 | RANK #848 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Colorectal Adenocarcinoma lists 10 open slots (50% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Colorectal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Colorectal Adenocarcinoma is recruiting above its size-band peers.
10 of 20 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Colorectal Adenocarcinoma research.
City of Hope Medical Center accounts for 4 of 20 trials (20%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Colorectal Adenocarcinoma enrolment sits around 111 participants.
Median target enrolment is 111 among the 20 trials that report a genuine target (sentinel values excluded). 10 of those (50%) plan for fewer than 100 participants.
-
Colorectal Adenocarcinoma research is mostly interventional.
14 interventional and 6 observational studies make up this index (70% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Early Detection of Advanced Adenomas and Colorectal Cancer
City of Hope Medical Center
NCT06342440
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
M.D. Anderson Cancer Center
NCT04739072
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06051695
Early Onset Colorectal Cancer Detection
City of Hope Medical Center
NCT06342401
Stage II/III Colorectal Cancer Recurrence
City of Hope Medical Center
NCT06314958
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Aktis Oncology
NCT07020117
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics
NCT06778863
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
University of Chicago
NCT05200442
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
Yale University
NCT07291180
Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer
Jonsson Comprehensive Cancer Center
NCT06225011
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
NCT04094688
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co.
NCT05731271
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
NCT03368963
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Thomas Jefferson University
NCT04111172
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
NCT04963283
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
M.D. Anderson Cancer Center
NCT03599752
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
NCT04457284
Colvera for Detection of Disease Recurrence
Clinical Genomics Pathology
NCT03706235
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
City of Hope Medical Center
NCT06314971
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
TyrNovo
NCT04474470
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Colorectal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Colorectal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Colorectal Adenocarcinoma page
20 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Colorectal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Colorectal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Adenocarcinoma condition card totals 20 registered trials; most-linked intervention Nivolumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.